Posts by Peter W. PENG

From September 25 to 29, 2024, the highly anticipated 27th National Clinical Oncology Conference and CSCO Annual Meeting was successfully held in Xiamen. This prestigious event brought together top experts in the field of oncology from across China, focusing on standardized pathways for diagnosis and treatment of malignant tumors and exploring the latest frontiers. During the conference, Dr. Jun Zhou from Peking University Cancer Hospital delivered a presentation titled “Advances in the Application of New Anticancer Drugs in Biliary Tract Cancer” at the dedicated session on targeted therapy for cholangiocarcinoma. Oncology Frontier had the opportunity to conduct an in-depth interview with Professor Zhou, delving into the current progress in drug treatments for biliary tract cancers and exploring future research directions.

EGFR P-loop-aC helix compression (PACC) mutation is a recently identified subtype of EGFR mutations in non-small cell lung cancer (NSCLC), and its potential for precision therapy had not been clinically validated until now. At the 2024 World Conference on Lung Cancer (WCLC 2024), during the Presidential Symposium Presentation, the global phase Ib FURTHER trial's proof-of-concept results were revealed. Furmonertinib as monotherapy in first-line treatment of NSCLC patients with EGFR PACC mutations demonstrated outstanding efficacy and safety. Oncology Frontier  interviews the study’s principal investigator, Dr. Xiuning Le from the MD Anderson Cancer Center, to delve into how EGFR PACC mutations moved from concept to clinic and how Furmonertinib is pioneering targeted therapy for this subtype of lung cancer.

We are pleased to share an expert discussion with Dr. Peter Schmid on the findings from the pivotal Keynote 522 trial. This landmark Phase 3 study investigates the impact of combining chemotherapy with immunotherapy (Pembrolizumab) in early-stage triple-negative breast cancer (TNBC). The trial’s results highlight a 34% reduction in the risk of death, marking a significant advancement in patient outcomes and offering new hope for TNBC treatment strategies.

In the past, there has been ongoing debate about the therapeutic value of radiotherapy in resectable gastric cancer. The TOPGEAR study presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona) evaluated the comparison between preoperative chemoradiotherapy and perioperative chemotherapy alone. Dr. Trevor Leong, the Principal Investigator from the University of Melbourne in Australia, was interviewed by us on site.

The 27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting, hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, is about to open in Xiamen. This grand event will bring together top domestic and international experts to share the latest research results and practical experiences. Ahead of the conference, Oncology Frontier interviewed Dr. Jun Guo of Peking University Cancer Hospital, who reflected on CSCO's development over the past two decades. He also introduced the key features and value of the newly updated CSCO Guidelines for Melanoma Diagnosis and Treatment and the CSCO Patient Education Manual - Melanoma. Emphasizing early detection and treatment, Professor Guo highlighted the promising outlook for melanoma therapy in China, where patients can expect improved survival rates and better quality of life thanks to the emergence of new drugs and advanced treatment concepts.